Showing results (71-80 of 78) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Gigascience|March 3, 2020
Genome sequence of the agarwood tree Aquilaria sinensis (Lour.) Spreng: the first chromosome-level draft genome in the Thymelaeceae familyXupo Ding, Wenli Mei, Qiang Lin, et al.Journal of Virology|January 25, 2024
A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2Yingying Deng, Yamin Sheng, Guixi Zhang, et al.Human Vaccines & Immunotherapeutics|November 12, 2020
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trialShangying Hu, Xiaoqian Xu, Fengcai Zhu, et al.Nature Medicine|January 28, 2022
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Lihua Hou, Xiling Guo, et al.Asia-Pacific Journal of Clinical Oncology|September 14, 2022
Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: A 10-year follow-up studyFanghui Zhao, Archana Jastorff, Ying Hong, et al.Cancer Medicine|July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.Cancer Medicine|December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.The Lancet Regional Health. Western Pacific|September 19, 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialAi-Min Hui, Jingxin Li, Li Zhu, et al.Pageof 8